This has uncovered the potential of inhaled PPAR-γ agonists in the treatment of airway inflammation via the many cellular targets in the lung such as T lymphocytes, epithelial cells and smooth muscle cells with the possibility of delivering them locally, with minimal side effects, compared to the currently available corticosteroids [5]. This evidence concerns the gene PPARG and inflammatory response.